Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Metadata
Title
Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct
Authors
Gabriela Pavlinkova
David Colcher
Barbara J. M. Booth
Apollina Goel
Surinder K. Batra
Publication date
01-06-2000
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 4-5/2000
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620000108

Other articles of this Issue 4-5/2000

Cancer Immunology, Immunotherapy 4-5/2000 Go to the issue

ORIGINAL ARTICLE

Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors

ORIGINAL ARTICLE

Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies

ORIGINAL ARTICLE

Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis

SYMPOSIUM SERIES

New methods to approach immunotherapy of cancer – and strategies of tumours to avoid elimination

ORIGINAL ARTICLE

Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses

ORIGINAL ARTICLE

Functional assessment in vitro of human-complement-dependent antibody-induced cytotoxicity of neoplastic cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits